Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower respiratory tract disease ...

SPRINGFIELD, Mass. (WWLP) – Pfizer’s RSV vaccine also known as Abrysvo is showing the potential to protect adults ages 18 to 59 who are at high risk of getting sick. Officials investigate rare ...

The company is evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe LRTD as part of an ongoing pivotal Phase 3 clinical trial (MONeT ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly ...

Pregnant women can now get the maternal RSV vaccine, Abrysvo, for free under the National Immunisation Program (NIP), alongside ones for influenza and whooping cough. Abrysvo is available for ...